Page 38 - Michael Erman News Today

By Ahmed Aboulenein and Michael Erman WASHINGTON (Reuters) -The U.S. government will select the Medicare program's 10 costliest prescription medicines...

The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should... | March 13, 2023

The collapse of Silicon Valley Bank will leave early stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly traded drug companies should escape unscathed.

The White House budget request includes plans to strengthen the FDA’s regulatory authority.

The blood thinner Eliquis from Bristol Myers Squibb, Pfizers breast cancer drug Ibrance and AbbVies leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S.... | March 13, 2023

A panel of outside advisers to the US health regulator recommended Pfizer Incs respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.

By Manas Mishra (Reuters) - The frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - w...

US Senator Elizabeth Warren has sent the nations top patent regulator a letter urging close scrutiny of Mercks requests for new patents on its blockbuster cancer treatment Keytruda, saying further efforts to protect the drug could be an abuse of the system.

By Aditya Samal (Reuters) - There is not sufficient evidence to recommend more than one COVID-19 booster shot a year for older people and those with w...

By Aditya Samal (Reuters) - There is not sufficient evidence to recommend more than one COVID-19 booster shot a year for older people and those with w...